Cerevel Therapeutics Email Format

Pharmaceutical Manufacturing
50,001-100,000 employees
North Chicago, IL, USA

Cerevel Therapeutics is a neuroscience-focused biopharmaceutical company now part of AbbVie, dedicated to developing therapies for neurological and psychiatric disorders.

Find contacts at Cerevel Therapeutics

Search our verified sources for decision-makers, emails, and titles.

Start searching
VERIFIED BY CLAY

first.last@cerevel.com

Company Overview

Industry
Pharmaceutical Manufacturing
Founded
2018
Headquarters
North Chicago, IL, USA
Revenue
$50B-$100B
FUNDING Stage
Acquired
Key Executives
Susan Altschuller, Ph.D., MBA (Chief Financial Officer), Paul Burgess (Chief Business Development and Strategic Operations Officer), Kaya Pai Panandiker (Head of Commercial)

Tech Stack

Google Cloud

Cloud

Signup

to know

Signup

to know

Signup

to know

Key Executives

Chief Executive Officer

Find the current person →

Chief Finance Officer

Find the current person →

Chief Operating Officer

Find the current person →

Chief Technology Officer

Find the current person →

Chief Marketing Officer

Find the current person →

Chairman

Find the current person →

4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified

Frequently Asked Questions

What is the email format of Cerevel Therapeutics?

Cerevel Therapeutics uses the first.last format on cerevel.com, so Jane Smith would be jane.smith@cerevel.com.

What therapeutic areas does Cerevel Therapeutics focus on?

Cerevel Therapeutics focuses on neurological and neuropsychiatric conditions including Parkinson's disease, schizophrenia, epilepsy, major depressive disorder, and dementia-related apathy, with a pipeline built around selectively targeting specific brain receptor subtypes.

Which Cerevel Therapeutics drug candidate is furthest along in clinical development?

Tavapadon, Cerevel Therapeutics' investigational treatment for Parkinson's disease, reached Phase 3 clinical trials, making it the most advanced program in the company's pipeline before its acquisition by AbbVie in 2024.

How does Cerevel Therapeutics fit into AbbVie's neuroscience strategy?

AbbVie completed its acquisition of Cerevel Therapeutics in August 2024 for approximately 8.7 billion dollars, absorbing Cerevel's clinical-stage neuroscience pipeline to strengthen AbbVie's presence in neurological and psychiatric drug development.

Where can I find verified contact details for Cerevel Therapeutics employees?

Cerevel Therapeutics employees follow the first.last@cerevel.com format, and tools like Clay can help you verify individual addresses and build outreach lists for specific roles or teams within the organization.

Share Article

Get access to more people and company data using Clay

Leverage the power of 100+ data providers for industry-leading data coverage & quality.

4.9 rating

More Articles